Cheyne-Stokes breathing is a repeating cycle of breathing that gradually gets deeper, then shallower, then stops entirely for several seconds before starting again. Each full cycle typically lasts 45 to 90 seconds, and the pattern can continue for hours. It occurs most often during sleep in people with heart failure or after a stroke, though it can also appear in the final hours or days of life.
What the Pattern Looks and Sounds Like
If you’re watching someone with Cheyne-Stokes breathing, you’ll notice a distinct wave-like rhythm. Breaths start shallow and quiet, grow progressively deeper and faster (the crescendo phase), then taper off again until they become very shallow or stop entirely. That pause, called a central apnea, may last 10 to 30 seconds or more. Then the cycle starts over.
This is different from obstructive sleep apnea, where the person tries to breathe but the airway is physically blocked. In Cheyne-Stokes breathing, the brain temporarily stops sending the signal to breathe at all. There’s no choking or gasping against a closed throat. Instead, the chest simply goes still. A bed partner often describes it as the person “forgetting” to breathe, followed by increasingly heavy breathing that can sound labored or even panicked before it tapers off again.
Why the Brain Loses Control of Breathing
Normal breathing works on a feedback loop. Sensors in your blood vessels and brainstem monitor the level of carbon dioxide (CO2) in your blood. When CO2 rises, they signal the lungs to breathe faster. When it drops, breathing slows. In healthy people, this loop keeps CO2 within a narrow range and breathing stays steady.
In Cheyne-Stokes breathing, that feedback loop becomes unstable. The brain overreacts to changes in CO2, creating wild swings instead of smooth corrections. Here’s how the cycle unfolds: a small disturbance, like shifting between sleep stages, triggers a burst of faster breathing. That burst blows off too much CO2, and blood CO2 drops below a critical threshold called the apnea threshold. Once CO2 falls below that line, the brain stops sending breathing signals, and an apnea begins. During the pause, CO2 slowly builds back up. When it finally crosses the threshold again, the brain responds with another round of hyperventilation, overshooting again. The cycle repeats because the system never lands on a stable middle ground.
Two conditions make this instability far more likely. In heart failure, blood circulates slowly, so there is a long delay between when the lungs change CO2 levels and when the brain’s sensors detect the change. That delay is like trying to adjust the temperature of a shower with a 30-second lag between turning the knob and feeling the water change. You constantly overcorrect. In stroke and other brain injuries, the sensors themselves are damaged, making the feedback imprecise even without a circulation delay.
Who Develops Cheyne-Stokes Breathing
Heart failure is by far the most common underlying cause. Up to 40% of patients with congestive heart failure show this breathing pattern during sleep studies, and some research has found rates as high as 68% in study populations with more advanced disease. The worse the heart’s pumping function, the more likely the pattern is to appear, because the circulatory delay becomes more pronounced as the heart weakens.
Stroke is the second major cause, particularly when the damage involves the pons, a region deep in the brainstem that helps coordinate automatic breathing. Studies of acute brainstem strokes have found that Cheyne-Stokes breathing is most prominent when lesions are large and affect both sides of the pons. The pattern is not tied to one specific level of the brainstem so much as to how widespread the injury is.
Cheyne-Stokes breathing also appears in other settings: severe kidney failure, carbon monoxide poisoning, high-altitude exposure in healthy climbers, and at the end of life in people dying from a range of conditions. In healthy people at high altitude, the low-oxygen environment narrows the gap between normal CO2 levels and the apnea threshold, creating the same instability seen in heart failure patients.
When It Happens During Sleep
The pattern is most common during lighter stages of non-REM sleep, specifically stages N1 and N2. During these stages, the body relies almost entirely on chemical signals (CO2 levels) to drive breathing, and the “wakefulness drive” that helps keep breathing steady during the day is switched off. Transitions between sleep stages or brief arousals can trigger the initial burst of hyperventilation that kicks off a cycle.
During deeper sleep and REM sleep, breathing tends to stabilize somewhat, though severe cases can persist across all stages. The repeated arousals caused by the apnea phases fragment sleep significantly. People with Cheyne-Stokes breathing often experience excessive daytime sleepiness, poor concentration, and fatigue, not because they aren’t spending enough hours in bed, but because they rarely reach the deeper, restorative stages of sleep.
How It Is Diagnosed
Cheyne-Stokes breathing is formally identified through an overnight sleep study (polysomnography). The American Academy of Sleep Medicine requires two criteria for the diagnosis: at least three consecutive central apneas or shallow-breathing events separated by the characteristic crescendo-decrescendo pattern, with each cycle lasting at least 40 seconds, and at least five of these events per hour recorded over a minimum of two hours of monitoring.
In practice, the pattern is often first noticed by a caregiver, family member, or nurse rather than in a sleep lab. If someone with heart failure or a recent stroke displays the recognizable waxing-and-waning rhythm, a sleep study can confirm the diagnosis and measure its severity.
What It Means for Prognosis
Cheyne-Stokes breathing in heart failure is not just a sleep disturbance. It is a marker of how unstable the cardiovascular system has become. The pattern reflects both a weakened heart (causing the circulation delay) and heightened stress-hormone activity that further destabilizes breathing control. Patients with heart failure who develop Cheyne-Stokes breathing generally have more advanced disease and face a worse outlook than those who do not, though it remains an area of active clinical study to determine whether the breathing pattern itself worsens outcomes or simply reflects the severity of the underlying condition.
In the context of end-of-life care, Cheyne-Stokes breathing carries a different significance. When it appears in someone who is actively dying, it typically signals that the brain’s respiratory centers are shutting down. In this setting, it is one of several changes in breathing that indicate death may be hours to days away. It does not cause suffering for the person, who is usually unconscious or minimally aware by this point, though it can be distressing for family members to witness.
Treatment Options and Their Limits
Because Cheyne-Stokes breathing is almost always a consequence of another condition, the most effective treatment is addressing the underlying cause. Optimizing heart failure management, through medications that improve the heart’s pumping strength, reduce fluid overload, and lower stress-hormone activity, can reduce or eliminate the breathing pattern in many patients.
For patients whose Cheyne-Stokes breathing persists despite optimal heart failure treatment, supplemental oxygen during sleep is sometimes used to raise blood oxygen levels and reduce the sensitivity of the CO2 feedback loop. CPAP (continuous positive airway pressure), the same machine used for obstructive sleep apnea, has also been tried but showed no clear benefit for central sleep apnea in a large randomized trial called CANPAP.
A more advanced device called adaptive servo-ventilation (ASV) was designed specifically for this problem. It monitors breathing in real time and delivers variable air pressure to smooth out the crescendo-decrescendo swings. While ASV effectively suppresses the abnormal breathing pattern on a sleep study, a major trial published in the New England Journal of Medicine found that it did not improve outcomes for heart failure patients with reduced pumping function. In fact, it increased the risk of death from cardiovascular causes. As a result, ASV is now generally avoided in patients with significant heart failure, though it may still be used in patients whose Cheyne-Stokes breathing stems from other causes.
This paradox, a treatment that fixes the breathing pattern on paper but worsens survival, underscores that Cheyne-Stokes breathing is deeply entangled with the body’s cardiovascular and neurological systems. Treating the pattern in isolation, without addressing the failing heart or injured brain driving it, does not appear to help and may cause harm.